Warning: The NCBI web site requires JavaScript to function. more...
Clinical trial update: International Breast Cancer Study Group.
Price KN, Goldhirsch A; International Breast Cancer Study Group.
Breast Cancer Res. 2005;7(6):252-4. Epub 2005 Oct 4.
Related citations
Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: practical issues and factors associated with missing data.
Bernhard J, Peterson HF, Coates AS, Gusset H, Isley M, Hinkle R, Gelber RD, Castiglione-Gertsch M, Hürny C.
Stat Med. 1998 Mar 15-Apr 15;17(5-7):587-601.
Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group.
Bernhard J, Hürny C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Senn HJ, Rudenstam CM.
Ann Oncol. 1997 Sep;8(9):825-35. Erratum in: Ann Oncol 1998 Feb;9(2):231.
Clinical trial update: National Cancer Institute of Canada.
Pritchard K, Whelan T.
Breast Cancer Res. 2005;7(2):48-51. Epub 2005 Jan 12.
The best available adjuvant treatments are within the framework of clinical trials. The International Breast Cancer Study Group.
Goldhirsch A, Gelber RD, Castiglione M, Price KN, Rudenstam CM, Lindtner J, Collins J, Senn HJ, Cavalli F, Galligioni E, et al.
Isr J Med Sci. 1995 Feb-Mar;31(2-3):144-54.
The impact of the physician on the accrual to randomized clinical trials in patients with primary operable breast cancer.
Kaas R, Hart AA, Rutgers EJ.
Breast. 2005 Aug;14(4):310-6.
Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.
Monnier A.
Expert Rev Anticancer Ther. 2006 Oct;6(10):1355-9. Review.
Quality of life assessment in the International Breast Cancer Study Group: past, present, and future.
Hürny C, Bernhard J, Coates A.
Recent Results Cancer Res. 1998;152:390-5. Review.
Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J.
Clin Ther. 2005 Nov;27(11):1671-84. Review.
The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM.
Expert Rev Anticancer Ther. 2007 May;7(5):627-34. Review.
The future of surgical research: the role of the American College of Surgeons Oncology Group.
Posther KE, Wells SA Jr.
Eur J Surg Oncol. 2005 Aug;31(6):695-701. Epub 2005 Apr 26. Review.
A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
Jézéquel P, Campone M, Roché H, Gouraud W, Charbonnel C, Ricolleau G, Magrangeas F, Minvielle S, Genève J, Martin AL, Bataille R, Campion L.
Breast Cancer Res Treat. 2009 Aug;116(3):509-20. Epub 2008 Nov 20.
Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J, Perez EA, Pienkowski T, Bell R.
Oncologist. 2006;11 Suppl 1:4-12. Review.
[The new generation of breast cancer clinical trials: the right drug for the right target].
de Azambuja E, Cardoso F, Meirsman L, Straehle C, Dolci S, Vantongelen K, Piccart-Gebhart M.
Bull Cancer. 2008 Mar;95(3):352-7. Review. French.
A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.
Wapnir IL, Aebi S, Geyer CE, Zahrieh D, Gelber RD, Anderson SJ, Robidoux A, Bernhard J, Maibach R, Castiglione-Gertsch M, Coates AS, Piccart MJ, Clemons MJ, Costantino JP, Wolmark N; IBCSG; BIG; NSABP.
Clin Breast Cancer. 2008 Jun;8(3):287-92.
[Clinical and economic issues in adjuvant chemotherapy for HER-2 positive breast cancer].
Martins SJ, Yamamoto CA.
Rev Assoc Med Bras. 2008 Nov-Dec;54(6):494-9. Portuguese.
New criteria for selecting elderly patients for breast cancer adjuvant treatment studies.
Dellapasqua S, Colleoni M, Castiglione M, Goldhirsch A.
Oncologist. 2007 Aug;12(8):952-9.
Conservative local treatment versus mastectomy after induction chemotherapy in locally advanced breast cancer: a randomised phase III study (EORTC 10974/22002, LAMANOMA)--why did this study fail?
Sinacki M, Jassem J, van Tienhoven G.
Eur J Cancer. 2005 Dec;41(18):2787-8. Epub 2005 Nov 7. No abstract available.
Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment.
Vici P, Viola G, Rossi S, Botti C, Vitucci C, Sergi D, Ferranti FR, Saracca E, Di Lauro L, Corsetti S, Foggi P, Fattoruso SI, Lopez M.
Clin Ter. 2008 Nov-Dec;159(6):453-6. Review.
Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.
Taghian AG, Jeong JH, Mamounas EP, Parda DS, Deutsch M, Costantino JP, Wolmark N.
J Clin Oncol. 2006 Aug 20;24(24):3927-32.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on